Curative radiation for orbital MZL: How much? Journal Article


Author: Yahalom, J.
Article Title: Curative radiation for orbital MZL: How much?
Abstract: In this issue of Blood, Desai et al report a large retrospective analysis from the University of Miami including 182 patients with primary ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (orbital marginal zone lymphoma [MZL]).1 Most were at an early stage (82%), and 76% were treated successfully with orbital irradiation. Treatment and follow-up data spanned 31 years. This study reaffirms the excellent long-term control of orbital MZL with localized radiation therapy (RT; complete remission [CR] rate >97%); only 3 deaths were attributed to lymphoma, and 2 of those occurred following systemic transformation. © 2017 by The American Society of Hematology.
Keywords: cancer survival; overall survival; disease course; review; cancer recurrence; intensity modulated radiation therapy; treatment planning; cancer radiotherapy; radiation dose; outcome assessment; follow up; prospective study; progression free survival; relapse; risk factor; risk assessment; cause of death; electron therapy; biological activity; tumor cell; long term care; remission; retinopathy; prematurity; radiation dose distribution; marginal zone lymphoma; orbit tumor; lymph node irradiation; recurrence free survival; radiobiology; eradication therapy; proton therapy; neovascular glaucoma; lacrimal gland; cornea ulcer; conjunctiva; human; priority journal; optic nerve atrophy; patient risk; ocular adnexal mucosa associated lymphoid tissue lymphoma
Journal Title: Blood
Volume: 129
Issue: 3
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-01-19
Start Page: 270
End Page: 271
Language: English
DOI: 10.1182/blood-2016-11-749176
PROVIDER: scopus
PUBMED: 28104673
DOI/URL:
Notes: Review -- Export Date: 2 January 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Joachim Yahalom
    391 Yahalom